Chronic myeloid leukaemia remission stability after tyrosine - kinase inhibitors therapy cessation: a review of literature

Introduction: Chronic myeloid leukaemia (CML) is a specific malignant disease as it can be managed by a long-term oral tyrosine-kinase inhibitors (TKIs) treatment. Routine practise in the management of CML includes continuation of TKIs therapy even after the patient achieves remision. Several trials have demonstrated that TKIs discontinuation is feasible in clinical practice. The aim of this paper is to assess relevant scientific evidence on CML remission stability after TKIs therapy cessation.